News

Intas and Accord Join Forces to Enhance Pegfilgrastim Supply Globally

Intas and Accord Join Forces to Enhance Pegfilgrastim Supply Globally

Acquisition of UDENYCA® Enhances Global Presence

Intas Pharmaceuticals and Accord BioPharma have made a significant stride in their objectives within the biosimilar landscape through the acquisition of UDENYCA® (pegfilgrastim-cbqv). This strategic move solidifies their status as one of the largest global suppliers of pegfilgrastim, showcasing their commitment to increasing accessibility of high-quality treatments.

UDENYCA®: A Leap Forward in Biosimilars

The addition of UDENYCA to the Accord BioPharma portfolio is particularly noteworthy as it serves as a biosimilar to the widely used Neulasta® (pegfilgrastim). With this acquisition, the overall range of FDA-approved biosimilars offered by Intas and Accord is significantly bolstered. Accord has proven itself as a market leader in Europe by launching the first biosimilar pegfilgrastim, thus showcasing its ability to thrive despite the competitive atmosphere.

Patient-Centric Approaches

Accord BioPharma's mission continues with the commercialization of UDENYCA, aimed at reducing the risks of infection caused by febrile neutropenia in patients undergoing myelosuppressive chemotherapy. The product is available in three convenient formats: the autoinjector (AI), the on-body injector (OBI), and the prefilled syringe (PFS), catering to the diverse needs of patients and healthcare providers. The flexibility offered means treatment can be administered anywhere - at home, in a clinical setting, or on-the-go, thus empowering patients during their treatment journey.

Empowering the Workforce

This acquisition enhances not only the product offerings of Accord BioPharma but also brings aboard a multitude of skilled individuals from Coherus BioSciences. These professionals across various functions, including Sales, Marketing, and Manufacturing, will play a critical role in ensuring a seamless transition while leveraging their expertise to introduce UDENYCA to the market.

Leadership Perspectives

Chrys Kokino, U.S. President of Accord BioPharma, heralded the completion of the acquisition as a crucial milestone, expressing enthusiasm about the expanded capabilities that strengthen market presence. Furthermore, Paul Tredwell, the EMENA Executive Vice-President of Accord, emphasized that the commitment to commercializing UDENYCA® in multiple formats marks a significant advance in Accord's goal to lead the market for pegfilgrastim.

Commitment to Quality Care

Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals, reiterated the commitment to enhancing patient access to high-quality treatments, highlighting how this acquisition aligns with their broader corporate philosophy of innovation and quality.

Indications and Limitations of UDENYCA®

UDENYCA is indicated for decreasing the incidence of infection due to febrile neutropenia in non-myeloid malignancy patients on myelosuppressive chemotherapy and for increasing survival in patients exposed to high doses of radiation. However, it is not indicated for mobilizing peripheral blood progenitor cells for stem cell transplants, ensuring a focused application for appropriate patients only.

Safety Information

Important safety information includes contraindications for patients with a history of severe allergic reactions to pegfilgrastim products. Each patient must be monitored closely for possible adverse effects, including but not limited to splenic rupture and severe allergic reactions, to ensure their safety during treatment.

Conclusion: A New Chapter for Accord BioPharma

The acquisition of UDENYCA signifies a transformative step for both Intas and Accord BioPharma, not just in terms of their product availability but also in how they interact with and support patients undergoing treatment. This reinforces both companies' dedication to improving healthcare outcomes and signifies their prominent roles in the global biosimilars market.

Frequently Asked Questions

What is UDENYCA?

UDENYCA is a biosimilar medication indicated for reducing infection incidence due to febrile neutropenia in certain cancer patients.

How does the UDENYCA acquisition benefit patients?

The acquisition allows for expanded access to a high-quality pegfilgrastim treatment, with various administration options for patient convenience.

What role does Accord BioPharma play after this acquisition?

Accord BioPharma will lead the commercialization of UDENYCA, enhancing their presence in the biosimilar market.

Who are the key leaders at Accord BioPharma?

Chrys Kokino, Paul Tredwell, and Binish Chudgar are key leaders who have commented on the strategic significance of the acquisition.

What should patients know regarding UDENYCA's safety?

Patients must be aware of potential side effects and contraindications for UDENYCA, making it essential to consult healthcare providers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 130

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 50

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 75

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 99

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 50

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 49

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 81

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 54

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Huawei's Innovative Energy Solutions Drive Renewable Power Growth

Updated Category News Views 184

Transforming Energy Solutions with Huawei Digital Power At a prominent event in Germany, Huawei Digital Power made waves by showcasing cutting-edge solar and energy storage technologies. The company hosted an important launch event under the title "Smart PV & ESS: Powering a Grid Forming Future," emphasizing their commitment to advancing renewable energy solutions. With...

Continue Reading
Carlyle Credit Income Fund's NAV Insights and Latest Developments

Updated Category News Views 225

Understanding Carlyle Credit Income Fund's Latest NAV Report Carlyle Credit Income Fund (NYSE: CCIF) has recently unveiled its unaudited net asset value (NAV) per common share, reporting this figure as $7.64. This information was shared through a filing with the Securities and Exchange Commission, indicating the fund's current fiscal status. The announcement is important...

Continue Reading
Tuya Inc. to Announce Q4 and Fiscal Year 2025 Results Soon

Updated Category News Views 140

Tuya Inc. to Release Financial Results for Q4 and Fiscal Year 2025 Tuya Inc. (NYSE: TUYA), a prominent AI cloud platform service provider, has announced that it will share its fourth quarter and preliminary fiscal year 2025 financial results shortly after the market closes during the first week of March. This is a significant event for the company as it highlights the...

Continue Reading
Geopolitical Tensions Influence Oil Prices: Market Insights

Updated Category News Views 154

Current Oil Market Dynamics Amid Global Tensions Crude prices have shown significant resilience following earlier losses, positioning themselves for a potential third consecutive day of gains. As geopolitical tensions continue to escalate, the latest developments in the Middle East are fueling market reactions. Iran's Potential Military Actions and Market Implications...

Continue Reading
Antimony Market Growth: A Multi-Billion Dollar Future Ahead

Updated Category News Views 221

The Rising Antimony Market: A New Era of Opportunities Antimony minerals, primarily sourced from stibnite and its various forms, play a crucial role in multiple industries due to their unique properties such as flame retardancy and alloy formation. As societies continue to focus on enhancing safety in various applications, particularly in construction and automotive, the...

Continue Reading